• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Complicated Intra-Abdominal Infections - Pipeline Review, H2 2012 Product Image

Complicated Intra-Abdominal Infections - Pipeline Review, H2 2012

  • ID: 2244968
  • September 2012
  • 53 pages
  • Global Markets Direct

Complicated Intra-Abdominal Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Complicated Intra-Abdominal Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections. Complicated Intra-Abdominal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Complicated Intra-Abdominal READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Complicated Intra-Abdominal Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Complicated Intra-Abdominal Infections 7
Complicated Intra-Abdominal Infections Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Complicated Intra-Abdominal Infections Therapeutics – Products under Development by Companies 14
Companies Involved in Complicated Intra-Abdominal Infections Therapeutics Development 15
AstraZeneca PLC 15
Rib-X Pharmaceuticals, Inc. 16
Cubist Pharmaceuticals, Inc. 17
Paratek Pharmaceuticals, Inc. 18
Atox Bio Inc. 19
Tetraphase Pharmaceuticals Inc. 20
Complicated Intra-Abdominal Infections – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
omadacycline - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
delafloxacin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CXA201 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AB-103 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TP-434 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CAZ104 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CXA-201 + Metronidazole - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CAZ104 + Metronidazole - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Complicated Intra-Abdominal Infections Therapeutics – Drug Profile Updates 42
Complicated Intra-Abdominal Infections Therapeutics - Dormant Products 48
Complicated Intra-Abdominal Infections – Product Development Milestones 49
Featured News & Press Releases 49
Sep 05, 2012: Tetraphase Pharma To Present New Clinical And Preclinical Research On Antibiotic Portfolio At ICAAC 2012 49
Dec 13, 2011: Cubist Announces First Patient Dosed In Pivotal Global Phase III Trial Of CXA-201 For Complicated Intra-Abdominal Infections 49
Jun 16, 2005: FDA Approves Tygacil, First-in-class Antibiotic 50
May 26, 2005: The US FDA Approves New Indication For Merrem I.V for Complicated Skin and Skin Structure Infections 50
Jan 28, 2005: FDA Grants Tygacil (Tigecycline) NDA Priority Review Status 51
Aug 02, 2004: AstraZeneca Submits supplemental New Drug Application to the U.S. Food and Drug Administration for Merrem I.V for a new indication of skin and skin structure infections 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Number of Products Under Development for Complicated Intra-Abdominal Infections, H2 2012 7
Products under Development for Complicated Intra-Abdominal Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
AstraZeneca PLC, H2 2012 15
Rib-X Pharmaceuticals, Inc., H2 2012 16
Cubist Pharmaceuticals, Inc., H2 2012 17
Paratek Pharmaceuticals, Inc., H2 2012 18
Atox Bio Inc., H2 2012 19
Tetraphase Pharmaceuticals Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Complicated Intra-Abdominal Infections Therapeutics – Drug Profile Updates 42
Complicated Intra-Abdominal Infections Therapeutics – Dormant Products 48

List of Figures
Number of Products under Development for Complicated Intra-Abdominal Infections, H2 2012 7
Products under Development for Complicated Intra-Abdominal Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos